The ACQUIRE trial

Research output: Contribution to journalArticle

Abstract

Achievement of goal blood pressure values, particularly in high-risk categories of patients, still remains an unmet goal of the therapeutic approach to hypertension. The same conclusion can be drawn for patient adherence to antihypertensive drugs, which is a variable of major relevance for obtaining optimal blood pressure control in treated hypertensives. The ACQUIRE study has recently evaluated the efficacy and safety profile of either aliskiren monotherapy or aliskiren/hydrochlorothiazide combination treatment in a consistent number of stage 2 hypertensive patients, half of them complicated by obesity. The results show the effectiveness of aliskiren, particularly when combined with hydrochlothiazide, in achieving satisfactory blood pressure control. This is particularly the case for systolic blood pressure values, which have a major detrimental impact on cardiovascular risk profile and on cardiovascular events. The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment.

Original languageEnglish
Pages (from-to)1665-1667
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number10
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Blood Pressure
Safety
Hydrochlorothiazide
Drug Combinations
Patient Compliance
Antihypertensive Agents
Therapeutics
Obesity
Hypertension
aliskiren

Keywords

  • aliskiren
  • antihypertensive treatment
  • combination treatment
  • hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

The ACQUIRE trial. / Grassi, Guido.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 10, 07.2011, p. 1665-1667.

Research output: Contribution to journalArticle

Grassi, Guido. / The ACQUIRE trial. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 10. pp. 1665-1667.
@article{d9bd3f3fb7994ba7b4aaff7a0823766c,
title = "The ACQUIRE trial",
abstract = "Achievement of goal blood pressure values, particularly in high-risk categories of patients, still remains an unmet goal of the therapeutic approach to hypertension. The same conclusion can be drawn for patient adherence to antihypertensive drugs, which is a variable of major relevance for obtaining optimal blood pressure control in treated hypertensives. The ACQUIRE study has recently evaluated the efficacy and safety profile of either aliskiren monotherapy or aliskiren/hydrochlorothiazide combination treatment in a consistent number of stage 2 hypertensive patients, half of them complicated by obesity. The results show the effectiveness of aliskiren, particularly when combined with hydrochlothiazide, in achieving satisfactory blood pressure control. This is particularly the case for systolic blood pressure values, which have a major detrimental impact on cardiovascular risk profile and on cardiovascular events. The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment.",
keywords = "aliskiren, antihypertensive treatment, combination treatment, hypertension",
author = "Guido Grassi",
year = "2011",
month = "7",
doi = "10.1517/14656566.2011.577067",
language = "English",
volume = "12",
pages = "1665--1667",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - The ACQUIRE trial

AU - Grassi, Guido

PY - 2011/7

Y1 - 2011/7

N2 - Achievement of goal blood pressure values, particularly in high-risk categories of patients, still remains an unmet goal of the therapeutic approach to hypertension. The same conclusion can be drawn for patient adherence to antihypertensive drugs, which is a variable of major relevance for obtaining optimal blood pressure control in treated hypertensives. The ACQUIRE study has recently evaluated the efficacy and safety profile of either aliskiren monotherapy or aliskiren/hydrochlorothiazide combination treatment in a consistent number of stage 2 hypertensive patients, half of them complicated by obesity. The results show the effectiveness of aliskiren, particularly when combined with hydrochlothiazide, in achieving satisfactory blood pressure control. This is particularly the case for systolic blood pressure values, which have a major detrimental impact on cardiovascular risk profile and on cardiovascular events. The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment.

AB - Achievement of goal blood pressure values, particularly in high-risk categories of patients, still remains an unmet goal of the therapeutic approach to hypertension. The same conclusion can be drawn for patient adherence to antihypertensive drugs, which is a variable of major relevance for obtaining optimal blood pressure control in treated hypertensives. The ACQUIRE study has recently evaluated the efficacy and safety profile of either aliskiren monotherapy or aliskiren/hydrochlorothiazide combination treatment in a consistent number of stage 2 hypertensive patients, half of them complicated by obesity. The results show the effectiveness of aliskiren, particularly when combined with hydrochlothiazide, in achieving satisfactory blood pressure control. This is particularly the case for systolic blood pressure values, which have a major detrimental impact on cardiovascular risk profile and on cardiovascular events. The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment.

KW - aliskiren

KW - antihypertensive treatment

KW - combination treatment

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=79958721185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958721185&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.577067

DO - 10.1517/14656566.2011.577067

M3 - Article

C2 - 21521132

AN - SCOPUS:79958721185

VL - 12

SP - 1665

EP - 1667

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -